Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfa-2b + PD-1 inhibitor
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Xiamen University
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
Peginterferon alfa-2b + PD-1 inhibitor is an investigational combination immunotherapy being evaluated by The First Affiliated Hospital of Xiamen University for the treatment of advanced or metastatic solid tumors. The regimen consists of **peginterferon alfa-2b**, a long-acting pegylated interferon that acts as an immunomodulator, and an **anti-PD-1 monoclonal antibody**, which clinical trial records (NCT04615390) identify as **toripalimab**. Peginterferon alfa-2b enhances the immune response by binding to the interferon-alpha/beta receptors (IFNAR1 and IFNAR2), thereby promoting MHC class I expression on tumor cells and activating natural killer (NK) cells and cytotoxic T lymphocytes. The PD-1 inhibitor component blocks the programmed cell death protein 1 (PD-1) receptor on T cells, preventing its interaction with ligands PD-L1 and PD-L2, which restores T-cell mediated anti-tumor activity. This combination aims to provide synergistic therapeutic effects by combining direct immune stimulation with the reversal of checkpoint-mediated immune exhaustion.
- Other names
- Peg-IFNα2b + anti-PD-1 antibodyPeginterferon alfa-2b + toripalimabPeg-IFNα2b + Toripalimab
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)PDCD1 (Programmed cell death protein 1 receptor)IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on peginterferon alfa-2b + PD-1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfa-2b + PD-1 inhibitor.